Published Online
on May 17, 2004

A more recent version of this article appeared on June 8, 2004

This Article Full Text (PDF) All Versions of this Article: 109/22/2755    most recent 01.CIR.0000130162.11925.21v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bilgin, Y. M. Articles by Brand, A. Search for Related Content PubMed PubMed Citation Articles by Bilgin, Y. M. Articles by Brand, A. Related Collections CV surgery: valvular disease CV surgery: other

Submitted on September 3, 2003
Revised on December 23, 2003
Accepted on February 26, 2004

Double-Blind, Randomized Controlled Trial on the Effect of Leukocyte-Depleted Erythrocyte Transfusions in Cardiac Valve Surgery

Y. M. Bilgin MD^*, L. M.G. van de Watering MD, L. Eijsman MD, PhD, M. I.M. Versteegh MD, R. Brand PhD, M. H.J. van Oers MD PhD, and A. Brand MD, PhD

From the Department of Hematology (Y.M.B., M.H.J.v.O.) and the Department of Cardiothoracic Surgery (L.E.), Academic Medical Center, Amsterdam, The Netherlands; and the Department of Immnunohematology and Blood Transfusion and Sanquin Bloodbank Southwest (L.M.G.v.d.W, A.B.), the Department of Cardiothoracic Surgery (M.I.M.V.), and the Department of Medical Statistics (R.B.), Leiden University Medical Center, Leiden, The Netherlands.

^* To whom correspondence should be addressed. E-mail: m.y.bilgin{at}lumc.nl.

Background--Leukocytes in allogeneic blood transfusions are believed to be the cause of immunomodulatory events. A few trials on leukocyte removal from transfusions in cardiac surgery have been conducted, and they showed inconclusive results. We found in a previous study a decrease in mortality rates and number of infections in a subgroup of more heavily transfused patients.

Methods and Results--Patients (n=496) undergoing valve surgery (with or without CABG) were randomly assigned in a double-blind fashion to receive standard buffy coat-depleted (PC) or prestorage, by filtration, leukocyte-depleted erythrocytes (LD). The primary end point was mortality at 90 days, and secondary end points were in-hospital mortality, multiple organ dysfunction syndrome, infections, intensive care unit stay, and hospital stay. The difference in mortality at 90 days was not significant (PC 12.7% versus LD 8.4%; odds ratio [OR], 1.52; 95% confidence interval [CI], 0.84 to 2.73). The in-hospital mortality rate was almost twice as high in the PC group (10.1% versus 5.5% in the LD group; OR, 1.99; 95% CI, 0.99 to 4.00). The incidence of multiple organ dysfunction syndrome in both groups was similar, although more patients with multiple organ dysfunction syndrome died in the PC group. LD was associated with a significantly reduced infection rate (PC 31.6% versus LD 21.6%; OR, 1.64; 95% CI, 1.08 to 2.49). In both groups, intensive care unit stay and hospital stay were similar, and postoperative complications increased with the number of transfused units.

Conclusions--Mortality at 90 days was not significantly different; however, a beneficial effect of LD in valve surgery was found for the secondary end points of in-hospital mortality and infections.

Key words: leukocytes • infection • mortality • bypass • valves

This article has been cited by other articles:

				B. J. Doyle, C. S. Rihal, D. A. Gastineau, and D. R. Holmes Jr Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention implications for contemporary practice. J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2019 - 2027. [Abstract] [Full Text] [PDF]

				S L Morley Red blood cell transfusions in acute paediatrics Arch. Dis. Child. Ed. Pract., June 1, 2009; 94(3): 65 - 73. [Abstract] [Full Text] [PDF]

				E. C. Vamvakas and M. A. Blajchman Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention Blood, April 9, 2009; 113(15): 3406 - 3417. [Abstract] [Full Text] [PDF]

				T. McGrath, C. G. Koch, M. Xu, L. Li, T. Mihaljevic, P. Figueroa, and E. H. Blackstone Platelet Transfusion in Cardiac Surgery Does Not Confer Increased Risk for Adverse Morbid Outcomes Ann. Thorac. Surg., August 1, 2008; 86(2): 543 - 553. [Abstract] [Full Text] [PDF]

				J. Zacharias, D. Lerman, and A. Knowles Blood Transfusion After Cardiac Surgery: Damned if You Don't. Damned if You Do? Ann. Thorac. Surg., June 1, 2007; 83(6): 2260 - 2260. [Full Text] [PDF]

				The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al. Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86. [Abstract] [Full Text] [PDF]

				J. Lacroix, P. C. Hebert, J. S. Hutchison, H. A. Hume, M. Tucci, T. Ducruet, F. Gauvin, J.-P. Collet, B. J. Toledano, P. Robillard, et al. Transfusion Strategies for Patients in Pediatric Intensive Care Units N. Engl. J. Med., April 19, 2007; 356(16): 1609 - 1619. [Abstract] [Full Text] [PDF]

				R. R. Verma, J. B. Williamson, H. Dashti, D. Patel, and N. J. Oxborrow Homologous blood transfusion is not required in surgery for adolescent idiopathic scoliosis. J Bone Joint Surg Br, September 1, 2006; 88-B(9): 1187 - 1191. [Abstract] [Full Text] [PDF]

				E. Hickey, T. Karamlou, J. You, and R. M. Ungerleider Effects of Circuit Miniaturization in Reducing Inflammatory Response to Infant Cardiopulmonary Bypass by Elimination of Allogeneic Blood Products Ann. Thorac. Surg., June 1, 2006; 81(6): S2367 - S2372. [Abstract] [Full Text] [PDF]